Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) in solid tumors: results from the pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts

被引：1
|
作者：
George, B. [1 ,2 ]
Kelly, K. [3 ]
Ko, A. [4 ]
Soliman, H. [5 ]
Trunova, N. [6 ]
Wainberg, Z. [7 ]
Waterhouse, D. [8 ]
O'Dwyer, P. [9 ]
Hochster, H. [10 ]
机构：
[1] Froedtert, Div Hematol & Oncol, Milwaukee, WI USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Univ Calif Davis, Ctr Comprehens Canc, Internal Med, Sacramento, CA USA
[4] Celgene Corp, Biostats, Summit, NJ USA
[5] Univ S Florida, Moffitt Canc Ctr, Tampa, FL USA
[6] Celgene Corp, Med Affairs, Summit, NJ USA
[7] Univ Calif Los Angeles, David Geffen Sch Med, Internal Med, Los Angeles, CA 90095 USA
[8] Oncol Hematol Care, Med Oncol, Cincinnati, OH USA
[9] Univ Penn, Abramson Canc Ctr, Med, Philadelphia, PA 19104 USA
[10] Yale Canc Ctr, Med Oncol, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw378.13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1059P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Interim results from the phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) in pancreatic cancer (PC), non-small cell lung cancer (NSCLC), and metastatic breast cancer (mBC)
    Wainberg, Z. A.
    George, B.
    Goldman, J. W.
    Hochster, H. S.
    Kelly, K.
    Ko, A.
    O'Dwyer, P. J.
    Trunova, N.
    Waterhouse, D.
    Soliman, H. H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S103 - S103
  • [2] Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.
    Wainberg, Zev A.
    Hochster, Howard S.
    George, Ben
    Gutierrez, Martin
    Johns, Mark Emery
    Chiorean, E. Gabriela
    Kwak, Eunice Lee
    Kalyan, Aparna
    Manax, Victoria
    Ye, Moncy
    Chen, Tianlei
    Trunova, Nataliya
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [3] Nivolumab (nivo) plus nab-paclitaxel (nab-P) plus carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study.
    Waterhouse, David Michael
    Goldman, Jonathan Wade
    George, Ben
    O'Dwyer, Peter J.
    Ye, Moncy
    Chen, Tianlei
    Trunova, Nataliya
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Phase I study of nivolumab (Nivo) plus nab-paclitaxel (nab-P) plus gemcitabine (Gem) in advanced pancreatic cancer (APC).
    Wainberg, Zev A.
    Hochster, Howard S.
    Kim, Edward Jae-Hoon
    George, Ben
    Kalyan, Aparna
    Chiorean, E. Gabriela
    Waterhouse, David Michael
    Gutierrez, Martin
    Parikh, Aparna Raj
    Jain, Rishi
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Bhore, Rafia
    Banerjee, Sibabrata
    Lyons, Larry
    Louis, Chrystal Ursula
    Ong, Teng Jin
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [5] Phase 1 study of nivolumab (nivo) plus nab-paclitaxel (nab-P) ± gemcitabine (G) in pancreatic cancer (PC): safety evaluation of patients treated with nivo plus nab-P in arm A
    Hochster, Howard S.
    Wainberg, Zev A.
    Gutierrez, Martin
    Waterhouse, David
    Chiorean, E. Gabriela
    George, Ben
    Ko, Amy
    Manax, Victoria
    Stergiopoulos, Sotirios
    O'Dwyer, Peter
    CANCER RESEARCH, 2016, 76
  • [6] nab-paclitaxel (nab-P) plus nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).
    Firdaus, Irfan
    Waterhouse, David Michael
    Gutierrez, Martin
    Wainberg, Zev A.
    George, Ben
    Kelly, Karen
    Bekaii-Saab, Tanios S.
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Fraser, Cindy Duval
    Ko, Amy
    Pierce, Daniel W.
    Manax, Victoria G.
    Stergiopoulos, Sotirios G.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) plus carboplatin (C) in advanced NSCLC: safety and efficacy results
    Waterhouse, David M.
    George, Ben
    Gutierrez, Martin
    Otterson, Greg A.
    Ko, Amy
    Ong, Teng Jin
    Stergiopoulos, Sotirios
    Trunova, Nataliya
    Kelly, Karen
    CANCER RESEARCH, 2016, 76
  • [8] Interim Results From the Phase I Study of Nivolumab plus nab-Paclitaxel plus Carboplatin in Non-Small Cell Lung Cancer (NSCLC)
    Goldman, Jonathan W.
    George, Ben
    Gutierrez, Martin
    Ko, Amy
    O'Dwyer, Peter
    Otterson, Gregory
    Soliman, Hatem
    Trunova, Nataliya
    Waterhouse, David
    Kelly, Karen
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1309 - S1309
  • [9] Phase I Study of Nivolumab plus Nab-Paclitaxel in Solid Tumors: Preliminary Analysis of the Non-Small Cell Lung Cancer Cohort
    George, Ben
    Kelly, Karen
    Ko, Amy
    Soliman, Hatem
    Trunova, Nataliya
    Wainberg, Zev
    Waterhouse, David
    O'Dwyer, Peter
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S211 - S212
  • [10] A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations
    Baik, Christina
    Goulart, Bernardo
    Nguyen, Katherine
    Lee, Sylvia
    Eaton, Keith
    Chow, Laura
    Rodriguez, Cristina
    Santana-Davila, Rafael
    Wood, Rebecca
    Martins, Renato
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1227 - S1227
12345